' 
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.3
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3
25 mcg (1,000 IU)
125%
Top Medical Research Studies
7
Vitamin D3 shows comparable effects
Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial.
Relevant to pediatric colitis treatments
We conducted a randomized controlled trial to investigate how vitamin D3 impacts children with inflammatory bowel disease (IBD), specifically aiming to address vitamin D deficiency in those suffering from colitis.
The study compared two different treatment approaches: a low daily dose of 2000 IU of vitamin D3 and a one-time high dose of the 'stoss' therapy, where children received a significantly larger dose of 400,000 IU or 800,000 IU, depending on their age. Children in both treatment groups were monitored over 12 months for various health indicators, including 25OHD levels and clinical disease activity.
Our findings revealed that the stoss therapy was non-inferior to the daily dosing regimen in raising vitamin D levels over the study period. Importantly, there were no significant differences in vitamin D levels at any of the checkpoints—3, 6, 9, or 12 months.
This indicates that both supplementation methods can effectively address vitamin D deficiency in children with colitis. However, the study emphasizes the absence of any superior benefits from one treatment over the other.
The study compared two different treatment approaches: a low daily dose of 2000 IU of vitamin D3 and a one-time high dose of the 'stoss' therapy, where children received a significantly larger dose of 400,000 IU or 800,000 IU, depending on their age. Children in both treatment groups were monitored over 12 months for various health indicators, including 25OHD levels and clinical disease activity.
Our findings revealed that the stoss therapy was non-inferior to the daily dosing regimen in raising vitamin D levels over the study period. Importantly, there were no significant differences in vitamin D levels at any of the checkpoints—3, 6, 9, or 12 months.
This indicates that both supplementation methods can effectively address vitamin D deficiency in children with colitis. However, the study emphasizes the absence of any superior benefits from one treatment over the other.
Read More
9
Vitamin D3 enhances colitis treatment
Co-administration of 1,25-dihydroxyvitamin D3 and infliximab improves colitis in mice by modulating Treg differentiation.
Context of vitamin D3 therapy
We explored the effects of combining infliximab (a TNF-α inhibitor) and vitamin D3 in treating ulcerative colitis (UC) using a mouse model. This approach aimed to understand better whether vitamin D3 could enhance the effectiveness of infliximab, particularly for patients who may not tolerate standard doses of the medication.
Our findings revealed that this combination therapy was beneficial. Not only did infliximab and vitamin D3 work together to improve clinical signs and reduce intestinal inflammation, but they also demonstrated a significant impact on a type of immune cell known as Regulatory T cells (Tregs). The combination led to increased production of helpful substances like IL-10, which plays a role in inflammation control.
Interestingly, we noticed that using vitamin D3 alongside a lower dose of infliximab resulted in similar effects as using a higher dose of infliximab alone. This suggests that vitamin D3 can enhance the therapeutic effects of infliximab, providing an effective alternative for patients who might struggle with standard treatments. Overall, our study highlights the potential of vitamin D3 as a valuable addition to managing ulcerative colitis.
Our findings revealed that this combination therapy was beneficial. Not only did infliximab and vitamin D3 work together to improve clinical signs and reduce intestinal inflammation, but they also demonstrated a significant impact on a type of immune cell known as Regulatory T cells (Tregs). The combination led to increased production of helpful substances like IL-10, which plays a role in inflammation control.
Interestingly, we noticed that using vitamin D3 alongside a lower dose of infliximab resulted in similar effects as using a higher dose of infliximab alone. This suggests that vitamin D3 can enhance the therapeutic effects of infliximab, providing an effective alternative for patients who might struggle with standard treatments. Overall, our study highlights the potential of vitamin D3 as a valuable addition to managing ulcerative colitis.
Read More
9
Butyrate and vitamin D3 benefits
Unveiling the Novel Benefits of Co-Administering Butyrate and Active Vitamin D3 in Mice Subjected to Chemotherapy-Induced Gut-Derived Sepsis.
Limited focus on vitamin D3
We investigated the effects of combining butyrate and active vitamin D3 (1,25D3) to tackle colitis, particularly in the context of chemotherapy-induced gut-derived sepsis. Our study involved a controlled setting in mice, where we first established a model of gut-derived sepsis through oral administration of bacteria alongside chemotherapy.
Through this process, we administered butyrate and vitamin D3 to the mice. Our findings showed that the combination of these treatments significantly lessened the severity of colitis symptoms and helped prevent the bacteria from invading vital organs like the liver and spleen. The improvements were linked to a boost in protective cytokines and antimicrobial peptides in the cecum, as well as a reduction in specific proteins related to gut permeability.
Interestingly, these benefits were more substantial when both compounds were used together compared to when they were given individually. This suggests that combining postbiotics like butyrate with vitamin D3 could be a promising approach to managing complications from chemotherapy in cancer patients, although further studies would be essential to establish these effects in humans.
Through this process, we administered butyrate and vitamin D3 to the mice. Our findings showed that the combination of these treatments significantly lessened the severity of colitis symptoms and helped prevent the bacteria from invading vital organs like the liver and spleen. The improvements were linked to a boost in protective cytokines and antimicrobial peptides in the cecum, as well as a reduction in specific proteins related to gut permeability.
Interestingly, these benefits were more substantial when both compounds were used together compared to when they were given individually. This suggests that combining postbiotics like butyrate with vitamin D3 could be a promising approach to managing complications from chemotherapy in cancer patients, although further studies would be essential to establish these effects in humans.
Read More
Most Useful Reviews
8.8
Consistent results
Excellent quality! I need to take vitamin D, 1000 IU daily due to my ulcerative colitis. I notice a direct impact on my health and mood with Solgar, which consistently delivers positive results reflected in my blood work. It's the only brand I trust, as I’ve experienced negative effects from trying others. My colon worsens, and I feel down; however, returning to Solgar improves my condition within days. Please heed caution if taking higher doses of vitamin D, as it can lead to elevated calcium levels in the blood.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.3
- All Researches
9
Vitamin D3 enhances colitis treatment
Co-administration of 1,25-dihydroxyvitamin D3 and infliximab improves colitis in mice by modulating Treg differentiation.
Context of vitamin D3 therapy
We explored the effects of combining infliximab (a TNF-α inhibitor) and vitamin D3 in treating ulcerative colitis (UC) using a mouse model. This approach aimed to understand better whether vitamin D3 could enhance the effectiveness of infliximab, particularly for patients who may not tolerate standard doses of the medication.
Our findings revealed that this combination therapy was beneficial. Not only did infliximab and vitamin D3 work together to improve clinical signs and reduce intestinal inflammation, but they also demonstrated a significant impact on a type of immune cell known as Regulatory T cells (Tregs). The combination led to increased production of helpful substances like IL-10, which plays a role in inflammation control.
Interestingly, we noticed that using vitamin D3 alongside a lower dose of infliximab resulted in similar effects as using a higher dose of infliximab alone. This suggests that vitamin D3 can enhance the therapeutic effects of infliximab, providing an effective alternative for patients who might struggle with standard treatments. Overall, our study highlights the potential of vitamin D3 as a valuable addition to managing ulcerative colitis.
Our findings revealed that this combination therapy was beneficial. Not only did infliximab and vitamin D3 work together to improve clinical signs and reduce intestinal inflammation, but they also demonstrated a significant impact on a type of immune cell known as Regulatory T cells (Tregs). The combination led to increased production of helpful substances like IL-10, which plays a role in inflammation control.
Interestingly, we noticed that using vitamin D3 alongside a lower dose of infliximab resulted in similar effects as using a higher dose of infliximab alone. This suggests that vitamin D3 can enhance the therapeutic effects of infliximab, providing an effective alternative for patients who might struggle with standard treatments. Overall, our study highlights the potential of vitamin D3 as a valuable addition to managing ulcerative colitis.
Read More
9
Butyrate and vitamin D3 benefits
Unveiling the Novel Benefits of Co-Administering Butyrate and Active Vitamin D3 in Mice Subjected to Chemotherapy-Induced Gut-Derived Sepsis.
Limited focus on vitamin D3
We investigated the effects of combining butyrate and active vitamin D3 (1,25D3) to tackle colitis, particularly in the context of chemotherapy-induced gut-derived sepsis. Our study involved a controlled setting in mice, where we first established a model of gut-derived sepsis through oral administration of bacteria alongside chemotherapy.
Through this process, we administered butyrate and vitamin D3 to the mice. Our findings showed that the combination of these treatments significantly lessened the severity of colitis symptoms and helped prevent the bacteria from invading vital organs like the liver and spleen. The improvements were linked to a boost in protective cytokines and antimicrobial peptides in the cecum, as well as a reduction in specific proteins related to gut permeability.
Interestingly, these benefits were more substantial when both compounds were used together compared to when they were given individually. This suggests that combining postbiotics like butyrate with vitamin D3 could be a promising approach to managing complications from chemotherapy in cancer patients, although further studies would be essential to establish these effects in humans.
Through this process, we administered butyrate and vitamin D3 to the mice. Our findings showed that the combination of these treatments significantly lessened the severity of colitis symptoms and helped prevent the bacteria from invading vital organs like the liver and spleen. The improvements were linked to a boost in protective cytokines and antimicrobial peptides in the cecum, as well as a reduction in specific proteins related to gut permeability.
Interestingly, these benefits were more substantial when both compounds were used together compared to when they were given individually. This suggests that combining postbiotics like butyrate with vitamin D3 could be a promising approach to managing complications from chemotherapy in cancer patients, although further studies would be essential to establish these effects in humans.
Read More
7
Vitamin D3 shows comparable effects
Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial.
Relevant to pediatric colitis treatments
We conducted a randomized controlled trial to investigate how vitamin D3 impacts children with inflammatory bowel disease (IBD), specifically aiming to address vitamin D deficiency in those suffering from colitis.
The study compared two different treatment approaches: a low daily dose of 2000 IU of vitamin D3 and a one-time high dose of the 'stoss' therapy, where children received a significantly larger dose of 400,000 IU or 800,000 IU, depending on their age. Children in both treatment groups were monitored over 12 months for various health indicators, including 25OHD levels and clinical disease activity.
Our findings revealed that the stoss therapy was non-inferior to the daily dosing regimen in raising vitamin D levels over the study period. Importantly, there were no significant differences in vitamin D levels at any of the checkpoints—3, 6, 9, or 12 months.
This indicates that both supplementation methods can effectively address vitamin D deficiency in children with colitis. However, the study emphasizes the absence of any superior benefits from one treatment over the other.
The study compared two different treatment approaches: a low daily dose of 2000 IU of vitamin D3 and a one-time high dose of the 'stoss' therapy, where children received a significantly larger dose of 400,000 IU or 800,000 IU, depending on their age. Children in both treatment groups were monitored over 12 months for various health indicators, including 25OHD levels and clinical disease activity.
Our findings revealed that the stoss therapy was non-inferior to the daily dosing regimen in raising vitamin D levels over the study period. Importantly, there were no significant differences in vitamin D levels at any of the checkpoints—3, 6, 9, or 12 months.
This indicates that both supplementation methods can effectively address vitamin D deficiency in children with colitis. However, the study emphasizes the absence of any superior benefits from one treatment over the other.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Consistent results
Excellent quality! I need to take vitamin D, 1000 IU daily due to my ulcerative colitis. I notice a direct impact on my health and mood with Solgar, which consistently delivers positive results reflected in my blood work. It's the only brand I trust, as I’ve experienced negative effects from trying others. My colon worsens, and I feel down; however, returning to Solgar improves my condition within days. Please heed caution if taking higher doses of vitamin D, as it can lead to elevated calcium levels in the blood.
Read More
